FDA Says Limited Availability Through July 2024 Of Mounjaro, Injection, 10 mg/.5 ml; Limited Availability Through July 2024 Of Zepbound, Injection, 10 mg/.5 ml
Portfolio Pulse from Benzinga Newsdesk
The FDA has announced limited availability of Mounjaro and Zepbound injections (10 mg/.5 ml) through July 2024.
July 02, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The FDA has announced limited availability of Eli Lilly's Mounjaro and Zepbound injections (10 mg/.5 ml) through July 2024, which could impact the company's sales and stock performance.
The limited availability of two key products, Mounjaro and Zepbound, could negatively impact Eli Lilly's sales and stock performance in the short term. Investors may react to potential revenue loss and supply chain issues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100